Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

IGF-1 HumanInterpret the evidence

What a 2026 cohort study found about circulating IGF-1 and epilepsy risk

2 numbered sourcesSource years 2026

Peptides are short chains of amino acids joined by peptide bonds. Longer chains can also act as signaling hormones. Human insulin-like growth factor 1 (IGF-1) is a 70-amino-acid hormone involved in growth and metabolism. A 2026 study looked at naturally circulating IGF-1 and asked whether blood concentrations measured before a diagnosis were associated with later epilepsy. [1, 2]

Researchers analyzed 466,857 UK Biobank participants with baseline IGF-1 measurements. During more than 15 years of follow-up, the study identified 4,532 people who developed epilepsy. The investigators used statistical models to adjust for several characteristics and looked at how the relationship changed across the range of measured concentrations. Lower blood IGF-1 was associated with a higher rate of new epilepsy diagnoses. The relationship was stronger at lower concentrations and appeared to flatten higher in the range. [1]

The study also asked a related but separate question about cognition. In participants who already had epilepsy, some initial cognitive associations did not remain statistically clear after the researchers adjusted for the number of comparisons. Analyses of cognitive performance in the larger cohort suggested associations in several domains, but those findings were not specific to people with epilepsy. Taken together, the data were clearer for the association with later epilepsy than for the cognitive outcomes. [1]

This was an observational human study. Researchers measured blood hormone concentrations and followed health records. They did not assign participants to receive IGF-1 or experimentally change their concentrations. Different health conditions or other characteristics can affect both a blood marker and a later diagnosis, even after a statistical model accounts for known factors. A blood concentration also describes the circulating hormone at the time of sampling and does not directly measure its activity in the brain. [1]

The result supports further work on whether IGF-1 could help researchers understand risk. It does not establish that changing circulating IGF-1 would change seizure risk or cognitive performance. Prescription mecasermin, a recombinant version of full-length human IGF-1, has defined U.S. indications for certain pediatric growth disorders. The 2026 cohort did not test that medicine. [1, 2]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop IGF-1 Human

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.